Blood-testing company Theranos plans to go out of business in the wake of one of the tech community’s biggest frauds, the Wall Street Journal reported Tuesday night.
The company plans to formally dissolve itself and pay unsecured creditors its remaining cash in coming months, the newspaper reported, citing an email sent to shareholders.
The announcement comes six months after Theranos and its chief executive, Elizabeth Holmes,with the US Securities and Exchange Commission in relation to false claims made about the company’s technology, business and financial performance.
The SEC charged Holmes and former President Ramesh “Sunny” Balwani with deceiving investors into believing the portable blood analyzer could conduct comprehensive blood tests from drops of blood. In reality, the SEC says, the analyzer could only complete a small number of tests, and the company “conducted the vast majority of patient tests on modified and industry-standard commercial analyzers manufactured by others.”
The SEC also alleged that claims the company would generate more than $100 million in revenue in 2014 were false, as it generated a little more than $100,000.
Once valued at $9 billion, the Newark, California-based company faced increased scrutiny, along with, since a Wall Street Journal report in October 2015 suggested its blood-testing devices were flawed.
In 2016, the federal Centers for Medicare & Medicaid Servicesfor two years and revoked the license for Theranos’ lab in California. And in May, the company from an investor claiming the company misled it to gain a nearly $100 million investment.
The Wall Street Journal reported that Theranosof its remaining employees in early April.
Theranos didn’t immediately respond to a request for comment.
Fight the Power: Take a look at who’s transforming the way we think about energy.
‘Hello, humans’: Google’s Duplex could make Assistant the most lifelike AI yet.